{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"323"}]}],"title":"Total Number of Corneal Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"158"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"158"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 4"}],"denomUnitsSelected":"Corneal Events","denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"323"}],"units":"Corneal Events"}],"description":"Ocular toxicity as measured by corneal events per the Keratopathy Visual Acuity scale, and graded using belantamab mafodotin REMS \\[Risk Evaluation and Mitigation Strategies\\] guidelines. Corneal examination changes from baseline are categorized as normal or grade 1, 2, 3, or 4 and are based on the worst overall finding. Normal: Cornea clear/No change from baseline. Grade 1: Mild superficial keratopathy with or without symptoms. Grade 2: Moderate superficial keratopathy. Grade 3: Severe superficial keratopathy. Moderate/Severe keratopathy could be with or without patchy microcyst-like deposits, sub-epithelial haze (peripheral), or a new peripheral stromal opacity. Grade 4: Corneal epithelial defect (such as corneal ulcer). The Data table reports the total number of corneal events experienced, along with counts and percentage by grade of event.","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"COUNT_OF_UNITS","populationDescription":"The 30 patients in the study experienced ocular toxicity (corneal events) a total of 323 times as reported during clinic visits. The analysis population is the 323 events reported.","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Ophthalmology: Grade of Ocular Toxicities (Corneal Events)","type":"POST_HOC","typeUnitsAnalyzed":"Corneal Events","unitOfMeasure":"Corneal Events"}